AstraZeneca
NEWS
The so-called “heart-in-a-jar” will be created from human stem cells and designed to reproduce key phenotypic characteristics of heart failure.
Effective treatments for diabetes are becoming more and necessary. The past few years have demonstrated productive strides in drug therapies, such as following medications.
As usual, it was a busy week for clinical trial updates. Here’s a look.
The latest approval for Calquence, a Bruton tyrosine kinase inhibitor, was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programs.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
It was a busy week for clinical trial announcements. Here’s a look.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The experimental drug, if approved, will compete with GlaxoSmithKline’s Benlysta, which is the only new drug approved for lupus in the last 60 years.
AstraZeneca is significantly expanding its footprint in China with the establishment of a global research and development center in the country, as well as the launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
JOBS
IN THE PRESS